[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011,61(2):69 [3] 唐鹏, 张洪典, 于振涛. 食管胃交界部腺癌根治术后早期复发的危险因素及预后分析[J]. 中华医学杂志, 2013,93(45):3594 [4] 赵敬柱, 张汝鹏, 王刚, 等. 进展期胃癌根治术后早期复发的危险因素分析[J]. 中华普通外科杂志, 2011,26(7):549 [10] 蔡荣耀, 黄志勇, 梁宾勇, 等. 原发性肝细胞癌根治术后肿瘤复发的影响因素及预后[J]. 中华消化外科杂志, 2011,10(4):263 [11] 邵淑丽, 柳晓肃. 卵巢上皮性癌的预后影响因素分析[J]. 中华妇产科杂志, 2010,45(2):132 [17] Brook R C, Tung K, Oeppen R. Batson’s plexus and retrograde venous spread of malignancy – a pictorial review[J]. Cancer Imaging the Official Publication of the International Cancer Imaging Society, 2014,14(Suppl 1):1 [19] 曹明, 赵宏, 穆鑫, 等. 吉西他滨联合顺铂方案新辅助化疗联合全膀胱切除术治疗肌层浸润性膀胱癌的9年回顾性分析[J]. 中华泌尿外科杂志, 2014,35(1):49 [21] Wang A X, Chang J W. Prognostic value of multiple-gene joint detection in bladder cancer[J]. Chinese? ?Clin Oncol , 2014,41(18):1190
[1]孟旭英,李珍瑾,郭剑超.组蛋白甲基转移酶EZH2抑制剂联合抗癌药物对膀胱癌细胞功能影响的研究[J].天津医科大学学报,2018,24(01):25.
MENG Xu-ying,LI Zhen-jin,GUO Jian-chao.Effect of histone methyltransferase EZH2 inhibitor combined with anticancer drugs on migration and proliferation of bladder cancer cells[J].Journal of Tianjin Medical University,2018,24(04):25.
[2]刘 莉 康家旗 综 述,刘晓强 审 校.膀胱癌外周血生物标志物研究进展[J].天津医科大学学报,2018,24(06):566.
[3]刘志飞,张志宏,邢力永,等.RRM1 mRNA与吉西他滨药物膀胱灌注治疗膀胱癌疗效的关系[J].天津医科大学学报,2019,25(01):51.
LIU Zhi-fei,ZHANG Zhi-hong,XING Li-yong,et al.The relationship between expression of RRM1 mRNA and efficacy of intravesical of gemcitabine in patients with nonmuscle-insive bladder caner[J].Journal of Tianjin Medical University,2019,25(04):51.
[4]付真睿,盛 飞,张昌文,等.SOX6在膀胱癌发生发展中的作用及相关机制[J].天津医科大学学报,2019,25(04):373.
FU Zhen-rui,SHENG Fei,ZHANG Chang-wen,et al.The characteristics of SOX6 in development of bladder cancer and relevant mechanism[J].Journal of Tianjin Medical University,2019,25(04):373.
[5]王银蕾,杨 瀚,高 杰,等.PITX2启动子甲基化及其与膀胱癌临床病理的关系[J].天津医科大学学报,2020,26(01):39.
WANG Yin-lei,YANG Han,GAO Jie,et al.Methylation of PITX2 promoter and relationship with clinical pathology of bladder cancer[J].Journal of Tianjin Medical University,2020,26(04):39.
[6]王玉杰,沈冲,高深,等.长链非编码RNA-FENDRR在膀胱癌组织中的表达及临床意义[J].天津医科大学学报,2020,26(05):445.
WANG Yu-jie,SHEN Chong,GAO Shen,et al.Expression of long non-coding RNA FENDRR in human bladder cancer tissues and Clinical significance[J].Journal of Tianjin Medical University,2020,26(04):445.
[7]朱建强,郑志文,付青峰,等.人工纳米材料在膀胱癌诊疗中的研究进展[J].天津医科大学学报,2022,28(05):563.
[8]陆益,于佳熙,梁政.氯丙嗪对膀胱癌BT-B细胞迁移功能的影响[J].天津医科大学学报,2022,28(06):621.
LU Yi,YU Jia-xi,LIANG Zheng.The effect of chlorpromazine on the migration of BT-B cellsin bladder cancer[J].Journal of Tianjin Medical University,2022,28(04):621.
[9]孙晓宇 张志宏 张昌文.膀胱癌类器官模型的研究进展[J].天津医科大学学报,2023,29(05):564.
[10]朱 亮,陈业刚.基于失巢凋亡相关标志物预测膀胱癌患者预后[J].天津医科大学学报,2024,30(01):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]
ZHU Liang,CHEN Yegang.Prognosis of patients with bladder cancer predicted by biomarker associated with anoikis[J].Journal of Tianjin Medical University,2024,30(04):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]
作者简介 陈可新(1989-),男,硕士在读,研究方向:泌尿外科;
通信作者:张志宏,E-mail:drzhangzhihong@163.com。